



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/714,689

11/17/2003

Sheng C. Lou

6755.US.D1

5738

23492

7590

07/27/2006

ROBERT DEBERARDINE

ABBOTT LABORATORIES

100 ABBOTT PARK ROAD

DEPT. 377/AP6A

ABBOTT PARK, IL 60064-6008

EXAMINER

PARKIN, JEFFREY S

ART UNIT

PAPER NUMBER

1648

DATE MAILED: 07/27/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/714,689	LOU ET AL.	
	Examiner	Art Unit	
	Jeffrey S. Parkin, Ph.D.	1648	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 03 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 23 June 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 27-39 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 27-39 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>11/17/2003</u> . | 6) <input type="checkbox"/> Other: _____ |

Serial No.: 10/714,689
Applicants: Lou, S. C., et al.

Docket No.: 6755.US.D1
Filing Date: 11/17/2003

Detailed Office Action

Status of the Claims

Claims 1-26 were canceled in the communication received 17 November, 2003, claims 27 and 28 amended, and new claims 29-39 introduced. Claims 27-39 are currently under examination.

37 C.F.R. § 1.98

The information disclosure statement filed 17 November, 2003, has been placed in the application file and the information referred to therein has been considered.

35 U.S.C. § 112, Second Paragraph

Claims 27-39 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Two separate requirements are set forth under this statute: (1) the claims must set forth the subject matter that applicants regard as their invention; and (2) the claims must particularly point out and distinctly define the metes and bounds of the subject matter that will be protected by the patent grant. The claims are vague and indefinite for failing to set forth all the salient characteristics of the claimed invention. For instance, both claims 27 and 28 are directed toward assay methods that appear to employ the simultaneous detection of both viral antigen and antibody in the same sample. However, the methods fail to provide sufficient assay steps and reagents that will allow the skilled artisan to accomplish this objective. In order to detect specific binding events the assay requires specific

detection reagents (i.e., labeled HIV-1 core antigen, labeled HIV-2 core antigen, labeled secondary antibody to a first HIV-specific primary antibody, etc.). In the absence of said assay steps, the claims fail to set forth the metes and bounds of the patent protection desired.

35 U.S.C. § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Biological Deposit Requirement

Claims 33, 38, and 39 are rejected under 35 U.S.C. § 112, first paragraph, as failing to provide an enabling disclosure for the claimed invention. It is apparent that the monoclonal antibodies 120A-270, 115B-151, 117-289, 103-350, 115B-303, and 108-394 are required to practice the claimed invention. As required elements, they must be known and readily available to the public or obtainable by a repeatable method set forth in the specification. If they are not so obtainable or available, the enablement requirements of 35 U.S.C. § 112, first paragraph, may be satisfied by a deposit of the hybridoma cell lines producing said antibodies. See 37 C.F.R. § 1.802.

Due to the unpredictability associated with antibody production (i.e., each antibody generally has a unique structure) and the failure of the specification to provide any detailed structural information concerning the claimed

antibodies, Mabs 120A-270, 115B-151, 117-289, 103-350, 115B-303, and 108-394 do not appear to be readily available materials.¹ Deposit of the hybridoma cell lines producing said antibodies or detailed structural information (i.e., the complete nucleotide or amino acid sequence of each antibody) would satisfy the enablement requirements of 35 U.S.C. § 112. If a deposit is made under the terms of the Budapest Treaty, then an affidavit or declaration by Applicants or someone associated with the patent owner who is in a position to make such assurances, or a statement by an attorney of record over his or her signature, stating that the deposit has been made under the terms of the Budapest Treaty and that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent, would satisfy the deposit requirements. See 37 C.F.R. § 1.808.

If the deposits have not been made under the provisions of the Budapest Treaty, then an affidavit or declaration by Applicants or someone associated with the patent owner who is in a position to make such assurances, or a statement by an attorney of record over his or her signature, stating that the deposit has been made at an acceptable depository and that the following criteria have been met:

- (a) during the pendency of the application, access to the deposits will be afforded to one determined by the Commissioner to be entitled thereto;

¹ It has been well-documented that most animals are capable of producing a vast repertoire of structurally and functionally distinct antibodies. For instance, conservative estimates suggest that humans are capable of producing over 32 million different combinations of light and heavy chains. This estimate excludes various other sources of diversity. See "Immunoglobulins: Molecular Genetics", in *Fundamental Immunology, Fourth Edition*, W. E. Paul, ed., Lippincott-Raven Publishers, Philadelphia, 1999, pp. 142-143.

(b) all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent;

(c) the deposits will be maintained for a term of at least thirty (30) years and at least five (5) years after the most recent request for the furnishing of a sample of the deposited material;

(d) a viability statement in accordance with the provisions of 37 C.F.R. § 1.807; and

(e) the deposit will be replaced should it become necessary due to inviability, contamination or loss of capability to function in the manner described in the specification.

In addition, the identifying information set forth in 37 C.F.R. § 1.809(d) should be added to the specification. See 37 C.F.R. §§ 1.803-1.809 for additional explanation of these requirements. It is noted that applicants stated in the communication dated 17 November, 2003, that hybridomas producing the claimed Mabs were deposited according to the terms of the Budapest Treaty. However, the response failed to contain a statement specifying that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent. Accordingly, the biological deposit requirements have not been fulfilled.

Written Description

Claims 27-39 are rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. *Univ. of Rochester v. G.D. Searle & Co., Inc.*, 358

F.3d 916, 920, 69 U.S.P.Q.2d 1886, (Fed. Cir. 2004). *Enzo Biochem, Inc. v. Gen-Probe, Inc.*, 296 F.3d 1316, 63 U.S.P.Q.2d 1609, (Fed. Cir. 2002). *Regents of the University of California v. Eli Lilly & Co.*, 119 F.3d 1559, 43 U.S.P.Q.2d 1398, (Fed. Cir. 1997). *Fiers v. Revel Co.*, 984 F.2d 1164, 25 U.S.P.Q.2d 1601, (Fed. Cir. 1993). *Amgen, Inc. v. Chugai Pharmaceutical Co.*, 927 F.2d 1200, 18 U.S.P.Q.2d 1016, (Fed. Cir. 1991). *In re Rasmussen*, 650 F.2d 1212, 211 U.S.P.Q. 323 (C.C.P.A. 1981). *In re Wertheim*, 541 F.2d 257, 191 U.S.P.Q. 90 (C.C.P.A. 1976).

To satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. See, e.g., *Vas-Cath, Inc., v. Mahurkar*, 935 F.2d at 1563, 19 U.S.P.Q.2d at 1116. The issue raised in this application is whether the original application provides adequate support for the broadly claimed genus of monoclonal antibodies that bind to a shared epitope of HIV-1 p24 and HIV-2 p26. An applicant shows possession of the claimed invention by describing the claimed invention with all of its limitations using such descriptive means as words, structures, figures, diagrams, and formulas that fully set forth the claimed invention. *Lockwood v. American Airlines, Inc.*, 107 F.3d 1565, 1572, 41 U.S.P.Q.2d 1961, 1966 (Fed. Cir. 1997). The claimed invention as a whole may not be adequately described where an invention is described solely in terms of a method of its making coupled with its function and there is no described or art-recognized correlation or relationship between the structure of the invention and its function. A biomolecule sequence described only by functional characteristic, without any known or disclosed correlation between that function and the structure of the sequence,

normally is not a sufficient identifying characteristic for written description purposes, even when accompanied by a method of obtaining the biomolecule of interest. *In re Bell*, 991 F.2d 781, 26 U.S.P.Q.2d 1529 (Fed. Cir. 1993). *In re Deuel*, 51 F.3d 1552, 34 U.S.P.Q.2d 1210 (Fed. Cir. 1995). A lack of adequate written description issue also arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product claimed from the disclosed process. See, e.g., *Fujikawa v. Wattanasin*, 93 F.3d 1559, 1571, 39 U.S.P.Q.2d 1895, 1905 (Fed. Cir. 1995). The court noted in this decision that a "laundry list" disclosure of every possible moiety does not constitute a written description of every species in a genus because it would not reasonably lead those skilled in the art to any particular species.

An applicant may show possession of an invention by disclosure of drawings or structural chemical formulas that are sufficiently detailed to show that applicant was in possession of the claimed invention as a whole. An applicant may also show that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics which provide evidence that applicant was in possession of the claimed invention, i.e., complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics. For some biomolecules, examples of identifying characteristics include a nucleotide or amino acid sequence, chemical structure, binding affinity, binding specificity, and molecular weight. The written description requirement may be satisfied through disclosure of function and minimal structure when there is a well-established correlation between structure and function.

Without such a correlation, the capability to recognize or understand the structure from the mere recitation of function and minimal structure is highly unlikely. In the latter case, disclosure of function alone is little more than a wish for possession; it does not satisfy the written description requirement. *Regents of the University of California v. Eli Lilly*, 119 F.3d 1559, 1566, 43 U.S.P.Q.2d 1398, 1404, 1406 (Fed. Cir. 1997), cert. denied, 523 U.S. 1089 (1998). *In re Wilder*, 736 F.2d 1516, 1521, 222 U.S.P.Q. 369, 372-3 (Fed. Cir. 1984). Factors to be considered in determining whether there is sufficient evidence of possession include the level of skill and knowledge in the art, partial structure, physical and/or chemical properties, functional characteristics alone or coupled with a known or disclosed correlation between structure and function, and the method of making the claimed invention.

The claims are broadly directed toward **any** Mab that recognizes **any** HIV-1/-2 shared antigenic determinant. However, the disclosure only provides a limited number of Mabs that meet the claimed limitations (e.g., 120A-270, 115B-151, 117-289, 103-350, 115B-303, and 108-394). Appropriate amendment of the claim language to reflect this finding would obviate the rejection. The disclosure does not provide sufficient support to place the applicants in possession of the entire genus of antibodies. First, the disclosure fails to provide adequate structural guidance pertaining to all the shared epitopes contained in HIV-1 p24 and HIV-2 p26. The skilled artisan cannot predict a priori which antigenic determinants are shared by both proteins. Second, the disclosure fails to provide adequate guidance pertaining to the structure of any given monoclonal antibody, particularly as it pertains to the complementarity binding regions. Once again, the skilled artisan cannot predict a

priori what the structure of any given Mab will be. Third, as set forth in points one and two, the skilled artisan would not be able to readily envisage the structure of any particular Mab. Fourth, as discussed in the preceding rejection, it has been well-documented that most animals are capable of producing a vast repertoire of structurally and functionally distinct antibodies. For instance, conservative estimates suggest that humans are capable of producing over 32 million different combinations of light and heavy chains. This estimate excludes various other sources of diversity. See "Immunoglobulins: Molecular Genetics", in *Fundamental Immunology, Fourth Edition*, W. E. Paul, ed., Lippincott-Raven Publishers, Philadelphia, 1999, pp. 142-143. Thus, the skilled artisan would reasonably conclude that applicants were not in possession of the full genus of antibodies.

35 U.S.C. § 103(a)

The following is a quotation of 35 U.S.C. § 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. § 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions

covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. § 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. § 103(c), and potential 35 U.S.C. § 102(e), (f) or (g) prior art under 35 U.S.C. § 103(a).

Claims 27-32 and 34-37 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Montagnier et al. (1991) and Butman et al. (1996). The claims are directed toward an HIV-1/-2 detection method that employs both an antigen-capture and antibody-capture format. Specifically, the claims employ HIV-1 and -2 core antigens (e.g., HIV-1 p24/25 and -2 p26), as well as, HIV-1 and -2 cross-reactive core antibodies. Montagnier and colleagues provide HIV-1/-2-specific antibody capture assays that employ both HIV-1 and -2 core antigens as the capture reagent. Butman and associates provide HIV-1/-2-specific antigen capture assays that employ a cross-reactive core antibody. Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine both art-recognized assay methods into a single format, since this would increase the overall sensitivity of the diagnostic assay by detecting both viral antigen and viral-specific antibody.

Non-statutory Double Patenting

The non-statutory double patenting rejection, whether of the obviousness-type or non-obviousness-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or

improper timewise extension of the "right to exclude" granted by a patent. *In re Thorington*, 418 F.2d 528, 163 U.S.P.Q. 644 (C.C.P.A. 1969); *In re Vogel*, 422 F.2d 438, 164 U.S.P.Q. 619 (C.C.P.A. 1970); *In re Van Ornum*, 686 F.2d 937, 214 U.S.P.Q. 761 (C.C.P.A. 1982); *In re Longi*, 759 F.2d 887, 225 U.S.P.Q. 645 (Fed. Cir. 1985); and *In re Goodman*, 29 U.S.P.Q.2d 2010 (Fed. Cir. 1993). A timely filed terminal disclaimer in compliance with 37 C.F.R. § 1.321(b) and (c) may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 C.F.R. § 1.78(d). Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 C.F.R. § 3.73(b).

Claims 27-39 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-7 of U.S. Patent No. 6,818,392 B2 in view of Montagnier et al. (1991). An obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but an examined application claim is not patentably distinct from the reference claim(s) because the examined claim is either anticipated by, or would have been obvious over, the reference claim(s). *In re Berg*, 140 F.3d 1428, 46 U.S.P.Q.2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 U.S.P.Q.2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 U.S.P.Q. 645 (Fed. Cir. 1985). Although the conflicting claims are not identical, they are not patentably distinct from each other. The claims of the '392 patent are directed toward an antigen capture assay employing the claimed

HIV-1/-2 cross-reactive antibodies. This teaching does not disclose a combination assay utilizing both an antigen and antibody capture format. Montagnier and colleagues provide an antibody capture assay employing both HIV-1 and -2 core antigens. Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine both art-recognized assay methods into a single format, since this would increase the overall sensitivity of the diagnostic assay by detecting both viral antigen and viral-specific antibody.


Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent related correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,



Jeffrey S. Parkin, Ph.D.
Primary Examiner
Art Unit 1648

23 July, 2006